This inventor holds 2 USPTO granted patents. Top assignee: Eli Lilly and Company. Active years: 2003-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003-2006
Title: The Innovations of Sharon Van den Berghe Snorek
Introduction
Sharon Van den Berghe Snorek is a distinguished inventor based in Lafayette, Indiana. With a focus on pharmaceutical and organic chemistry, Sharon has made significant contributions to the field with his inventive processes and formulations.
Latest Patents
Sharon holds two notable patents that showcase his expertise. The first is titled "Crystalline of N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-D]pyrimidin-5-YL)ethyl]benzoyl]-L-glutamic acid." This invention presents an improved method for preparing a novel heptahydrate crystalline salt of multitargeted antifolate, enhancing the efficacy of pharmaceutical applications. The second patent, "Formation and anion-exchange of crystalline echinocandin ammonium salts," details a meticulous method for forming crystalline Echinocandin nucleus salts using nanofiltration and specific chemical interactions, aimed at improving the production processes in pharmaceutical development.
Career Highlights
Sharon is currently associated with Eli Lilly and Company, a prominent player in the pharmaceutical industry. His work at Eli Lilly has allowed him to push the boundaries of drug formulation and delivery, making strides that benefit both the scientific community and patients worldwide.
Collaborations
Throughout his career, Sharon has collaborated with several talented individuals, including Erik Christopher Chelius and Susan Marie Reutzel-Edens. These partnerships highlight the interdisciplinary nature of pharmaceutical research, wherein diverse expertise converges to foster innovation.
Conclusion
Sharon Van den Berghe Snorek epitomizes the spirit of innovation within the pharmaceutical sector. His patents contribute to significant advancements in drug formulation and production processes, reflecting a commitment to improving health outcomes through innovative technology. As he continues his work at Eli Lilly and Company, one can anticipate further impactful contributions from this remarkable inventor.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile